作者
R Korenblik, B Olij, LA Aldrighetti, M Abu Hilal, Margareta Ahle, B Arslan, LJ van Baardewijk, I Baclija, C Bent, CL Bertrand, Bergthor Björnsson, MT de Boer, SW de Boer, RPH Bokkers, IHM Borel Rinkes, S Breitenstein, RCG Bruijnen, P Bruners, MW Büchler, JC Camacho, A Cappelli, U Carling, BKY Chan, DH Chang, J Choi, J Codina Font, M Crawford, D Croagh, E Cugat, R Davis, DW De Boo, F De Cobelli, Jean-François De Wispelaere, OM van Delden, M Delle, Olivier Detry, R Díaz-Nieto, Alexandra Dili, JI Erdmann, O Fisher, C Fondevila, Å Fretland, F Garcia Borobia, A Gelabert, Laurent Gérard, F Giuliante, PD Gobardhan, F Gómez, T Grünberger, DJ Grünhagen, J Guitart, J Hagendoorn, J Heil, D Heise, E Herrero, GF Hess, MH Hoffmann, R Iezzi, F Imani, J Nguyen, E Jovine, JC Kalff, G Kazemier, TP Kingham, J Kleeff, O Kollmar, WKG Leclercq, S Lopez Ben, V Lucidi, A MacDonald, DC Madoff, S Manekeller, G Martel, A Mehrabi, H Mehrzad, MR Meijerink, K Menon, P Metrakos, C Meyer, A Moelker, S Modi, N Montanari, J Navines, UP Neumann, P Peddu, JN Primrose, X Qu, D Raptis, F Ratti, F Ridouani, C Rogan, U Ronellenfitsch, S Ryan, C Sallemi, J Sampere Moragues, P Sandström, L Sarriá, A Schnitzbauer, M Serenari, A Serrablo, MLJ Smits, E Sparrelid, E Spüntrup, GA Stavrou, RP Sutcliffe, I Tancredi, JC Tasse, V Udupa, D Valenti, Y Fundora, TJ Vogl, X Wang, SA White, WA Wohlgemuth, D Yu, IAJ Zijlstra, CA Binkert, MHA Bemelmans, C van der Leij, E Schadde, RM van Dam
发表日期
2022/9
期刊
Cardiovascular and interventional radiology
卷号
45
期号
9
页码范围
1391-1398
出版商
Springer US
简介
Study Purpose
The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases.
Methods
The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the …
学术搜索中的文章
R Korenblik, B Olij, LA Aldrighetti, MA Hilal, M Ahle… - Cardiovascular and interventional radiology, 2022